Literature DB >> 17555370

New insights into the pathogenesis and treatment of anthrax toxin-induced shock.

Yan Li1, Kevin Sherer, Xizhong Cui, Peter Q Eichacker.   

Abstract

Inhalational Bacillus anthracis infection is a leading bioterrorist health threat in the US today. Lethal (LeTx) and edema toxin production are key to the virulent effects of this lethal bacteria. Recent insights into the structure and function of these toxins have increased the understanding of both the pathogenesis and treatment of anthrax. These are binary type toxins comprised of protective antigen necessary for their cellular uptake and either lethal or edema factors, the toxigenic moieties. Primary cellular receptors for protective antigen have been identified and the processing of the completed toxins clarified. Consistent with the ability of lethal factor to cleave mitogen activated protein kinase kinases, the evidence indicates that an excessive inflammatory response does not contribute to shock with LeTx. Rather, the immunosuppressive effects of LeTx could promote infection; however, direct endothelial dysfunction may have an important role in shock due to LeTx. Recent studies show that edema factor, a potent adenyl cyclase, may have a major role in shock during anthrax and that it may also be immunosuppresive. Therapies under development which target several steps in the cellular uptake and function of these two toxins have been effective in both in vitro and in vivo systems. Understanding how best to apply these agents in combination with conventional treatments should be a goal of future research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555370     DOI: 10.1517/14712598.7.6.843

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  9 in total

Review 1.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

2.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

3.  Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group.

Authors:  Feng Li; Irina Chvyrkova; Simon Terzyan; Nancy Wakeham; Robert Turner; Arun K Ghosh; Xuejun C Zhang; Jordan Tang
Journal:  Appl Microbiol Biotechnol       Date:  2012-01-25       Impact factor: 4.813

4.  Substrate specificity of the anthrax lethal factor.

Authors:  M Yu Zakharova; S A Dubiley; D M Chudakov; A G Gabibov; I G Shemyakin; A V Kolesnikov
Journal:  Dokl Biochem Biophys       Date:  2008 Jan-Feb       Impact factor: 0.788

5.  Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.

Authors:  Miriam M Ngundi; Bruce D Meade; Stephen F Little; Conrad P Quinn; Cindi R Corbett; Rebecca A Brady; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 6.  Cyclodextrin derivatives as anti-infectives.

Authors:  Vladimir A Karginov
Journal:  Curr Opin Pharmacol       Date:  2013-09-04       Impact factor: 5.547

7.  Pathology and pathophysiology of inhalational anthrax in a guinea pig model.

Authors:  Vladimir Savransky; Daniel C Sanford; Emily Syar; Jamie L Austin; Kevin P Tordoff; Michael S Anderson; Gregory V Stark; Roy E Barnewall; Crystal M Briscoe; Laurence Lemiale-Biérinx; Sukjoon Park; Boris Ionin; Mario H Skiadopoulos
Journal:  Infect Immun       Date:  2013-01-28       Impact factor: 3.441

Review 8.  Molecular determinants for a cardiovascular collapse in anthrax.

Authors:  Jurgen Brojatsch; Arturo Casadevall; David L Goldman
Journal:  Front Biosci (Elite Ed)       Date:  2014-01-01

9.  Two anthrax cases with soft tissue infection, severe oedema and sepsis in Danish heroin users.

Authors:  Lene Russell; Michael Pedersen; Andreas V Jensen; Lillian Marie Søes; Ann-Brit Eg Hansen
Journal:  BMC Infect Dis       Date:  2013-09-03       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.